Summary
Emcure Pharmaceuticals reduces its semaglutide starting dose price by 55%, enhancing accessibility for obesity treatment in India.
Source: BusinessLine
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
